|Table of Contents|

Prognostic value of the inflammatory composite index in non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 02
Page:
342-345
Research Field:
Publishing date:

Info

Title:
Prognostic value of the inflammatory composite index in non-small cell lung cancer
Author(s):
Wu Li1; Zheng Ling2
1.Zunyi Medical College，Guizhou Zunyi 563000，China；2.Oncology Department，Affiliated Hospital of Chengdu University，Sichuan Chengdu 610081，China.
Keywords:
tumor; non-small cell lung cancer; inflammation; prognosis
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.02.042
Abstract:
Lung cancer is a kind of inflammatory related disease and long-term chronic inflammation of lung may increase the risk of suffering from it.Non-small cell lung cancer,with the characteristics of high incidence,low early diagnosis rate and poor prognosis,is the most common type of lung cancer.Studies have shown that inflammatory response is widely involved in the initiation,proliferation,invasion and metastasis of tumor,which is closely related to the prognosis of the disease.Inflammatory composite indexes are expected to be effective indicators for the prognosis evaluation of non-small cell lung cancer.It is of practical significance to accurately assess the disease,identify the risk of survival and improve long-term prognosis.

References:

［1］ Torre LA,Siegel RL,Jemal A.Lung cancer statistics［J］.Advances in Experimental Medicine and Biology,2016,893:1-19.
[2] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.CA:A Cancer Journal for Clinicians,2016,66(2):115-132.
[3] Balkwill F,Mantovani A.Inflammation and cancer:Back to Virchow［J］?The Lancet,2001,357(9255):539-545.
[4] Coussens LM,Werb Z.Inflammation and cancer［J］.Nature,2002,420(6917):860-867.
[5] Douglas Hanahan，Robert A Weinberg.Hallmarks of cancer:The next generation［J］.Cell,2011,144(5):646-674.
[6] Grivennikov SI,Greten FR,Karin M.Immunity,inflammation,and cancer［J］.Cell,2010,140(6):883-899.
[7] Colotta F,Allavena P,Sica A,et al.Cancer-related inflammation,the seventh hallmark of cancer:Links to genetic instability［J］.Carcinogenesis,2009,30(7):1073-1081.
[8] Fan Y,Mao R,Yang J.NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer［J］.Protein & Cell,2013,4(3):176-185.
[9] Hussain SP,Harris CC.Inflammation and cancer:An ancient link with novel potentials［J］.International Journal of Cancer,2007,121(11):2373-2380.
[10] Park EJ,Lee JH,Yu GY,et al.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression［J］.Cell,2010,140(2):197-208.
[11] Brandau S.The dichotomy of neutrophil granulocytes in cancer［J］.Seminars in Cancer Biology,2013,23(3):139-140.
[12] Bremnes RM,Busund LT,Kilvaer TL,et al.The role of tumor-infiltrating lymphocytes in development,progression,and prognosis of non-small cell lung cancer［J］.Journal of Thoracic Oncology,2016,11(6):789-800.
[13] Zhang J,Huang SH,Li H,et al.Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer［J］.Medical Oncology,2013,30(1):352.
[14] Wang J,Kalhor N,Hu J,et al.Pretreatment neutrophil to lymphocyte ratio is associated with poor survival in patients with stage I-III non-small cell lung cancer［J］.PLoS One,2016,11(10):1-16.
[15] Cedrés S,Torrejon D,Martinez A,et al.Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer［J］.Clinical and Translational Oncology,2012,14(11):864-869.
[16] Lin GN,Peng JW,Liu PP,et al.Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment［J］.Asia-Pacific Journal of Clinical Oncology,2017,13(5):e189-e194.
[17] Guthrie GJ,Charles KA,Roxburgh CS,et al.The systemic inflammation-based neutrophil-lymphocyte ratio:Experience in patients with cancer［J］.Critical Reviews in Oncology/Hematology,2013,88(1):218-230.
[18] Chen C,Zhu YB,Shen Y,et al.Increase of circulating B7-H4-expressing CD68+ macrophage correlated with clinical stage of lung carcinomas［J］.Journal of Immunotherapy,2012,35(4):354-358.
[19] Zhang B,Yao G,Zhang Y,et al.M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma［J］.Clinics,2011,66(11):1879-1886.
[20] Porrata LF,Ristow K,Colgan JP,et al.Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma［J］.Haematologica,2012,97(2):262-269.
[21] Hu P,Shen H,Wang G,et al.Prognostic significance of systemic inflammation-based lymphocyte-monocyte ratio in patients with lung cancer:Based on a large cohort study［J］.PLoS One,2014,9(10):e108062.
[22] Song YJ,Wang LX,Hong YQ,et al.Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients［J］.Tumor Biology,2016,37(4):5285-5293.
[23] Chen YM,Lai CH,Chang HC,et al.Baseline,trend,and normalization of carcinoembryonic antigen as prognostic factors in epidermal growth factor receptor-mutant nonsmall cell lung cancer patients treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors［J］.Medicine,2015,94(50):e2239.
[24] Xia H,Sun Z,Deng L,et al.Prognostic significance of the preoperative lymphocyte to monocyte ratio in patients with stage I non-small cell lung cancer undergoing complete resection［J］.Cancer Investigation,2016,34(8):378-384.
[25] Liu H,Wu Y,Wang Z,et al.Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer［J］.Journal of Thoracic Disease,2013,5(6):783-789.
[26] Miyazaki T,Yamasaki N,Tsuchiya T,et al.Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer［J］.European Journal of Cardio-Thoracic Surgery,2014,47(4):e140-e145.
[27] Gu XB,Sun SQ,Gao XS,et al.Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer:Evidence from 3 430 patients［J］.Scientific Reports,2016,6:23893.
[28] Zhou X,Du Y,Huang Z,et al.Prognostic value of PLR in various cancers:A Meta-analysis［J］.PLoS One,2014,9(6):e101119.
[29] Hu B,Yang XR,Xu Y,et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma［J］.Clinical Cancer Research,2014,20(23):6212-6222.
[30] Hong X,Cui B,Wang M,et al.Systemic immune-inflammation index,based on platelet counts and neutrophil-lymphocyte ratio,is useful for predicting prognosis in small cell lung cancer［J］.The Tohoku Journal of Experimental Medicine,2015,236(4):297-304.
[31] Allin KH,Bojesen SE,Nordestgaard BG.Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer［J］.Journal of Clinical Oncology,2009,27(13):2217-2224.
[32] Jin Y,Zhao L,Peng F.Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer［J］.Clinics,2013,68(5):686-693.
[33] Tomita M,Ayabe T,Chosa E,et al.Prognostic significance of pre-and postoperative glasgow prognostic score for patients with non-small cell lung cancer［J］.Anticancer Research,2014,34(6):3137-3140.
[34] Lv Y,Pan Y,Dong C,et al.Modified glasgow prognostic score at recurrence predicts poor survival in resected non-small cell lung cancer (NSCLC) patients［J］.Medical Science Monitor,2017,23:3780-3788.
[35] Leung EY,Scott HR,McMillan DC.Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer［J］.Journal of Thoracic Oncology,2012,7(4):655-662.
[36] Zhou T,Zhan J,Hong S,et al.Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer［J］.Scientific Reports,2015,5(4):10481.
[37] Zhang F,Ying L,Jin J,et al.The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer［J］.Oncotarget,2017,8(5):8835-8842.

Memo

Memo:
-
Last Update: 1900-01-01